Prophylaxis of Pneumocystis Pneumonia in Immunocompromised Non--HIV-Infected Patients: Systematic Review and Meta-analysis of Randomized Controlled Trials

Green, Hefziba; Paul, Mical; Vidal, Liat; Leibovici, Leonard
September 2007
Mayo Clinic Proceedings;Sep2007, Vol. 82 Issue 9, p1052
Academic Journal
OBJECTIVE: To assess the efficacy of prophylaxis for Pneumocystis pneumonia (PCP), caused by Pneumocystis Jirovecil (formerly Pneumocystis carlnii), for immunocompromised non-HIV-infected patients by conducting a systematic review and meta-analysis. METHODS: We searched for randomized controlled trials that compared prophylaxis using antibiotics effective against P Jirovecil, given orally or intravenously, vs placebo, no intervention, or antibiotics with no activity against P Jirovecil. In addition, we included trials that compared different PCP prophylactic regimens or administration schedules. The search included the Cochrane Central Register of Controlled Trials, PubMed, Latin American and Caribbean Health Sciences Literature, and conference proceedings. No language, year, or publication restrictions were applied. Two reviewers (H.G. and M.P.) independently searched, selected trials, extracted data, and performed methodological quality assessment. Relative risks (RRs) with 95% confidence intervals (CIs) are reported. Meta-analysts was performed using the random-effects model. RESULTS: Twelve randomized trials were identified, including 1245 patients (50% children) who had undergone autologous bone marrow or solid organ transplant or who had hematologic cancer. When trimethoprim-sulfamethoxazole was administered, a 91% reduction was observed in the occurrence of PCP (RR, 0.09; 95% CI, 0.02-0.32); the number needed to treat was 15 (95% CI, 13-20) patients, with no heterogeneity. Pneumocystis pneumonia-related mortality was significantly reduced (RR, 0.17; 95% CI, 0.03-0.94), whereas all-cause mortality did not differ significantly (RR, 0.79; 95% CI, 0.18-3.46). Adverse events that required discontinuation occurred in 3.1% of adults and none of the children, and all were reversible. No differences between once-dally and thrice-weekly administration schedules were found. CONCLUSIONS: Balanced against severe adverse events, PCP prophylaxis is warranted when the risk for PCP is higher than 3.5% for adults. Adverse events are less frequent in children, for whom prophylaxis might be warranted at lower PCP incidence rates.


Related Articles

  • Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. Tasaka, Sadatomo; Tokuda, Hitoshi // Journal of Infection & Chemotherapy;Dec2012, Vol. 18 Issue 6, p793 

    In human immunodeficiency virus (HIV)-infected patients, Pneumocystis jirovecii pneumonia (PCP) is a well-known opportunistic infection, and its management has been established. However, PCP is an emerging threat to immunocompromised patients without HIV infection, such as those receiving novel...

  • Co-trimoxazole desensitization in HIV-seropositive patients. Theodore, C. M.; Holmes, D.; Rodgers, M.; McLean, K. A. // International Journal of STD & AIDS;Mar1998, Vol. 9 Issue 3, p158 

    Summary: Co-trimoxazole (trimethoprim-sulphamethoxazole) is an effective prophylactic agent against Pneumocystis carinii pneumonia (PCP). However, it is associated with a high frequency of adverse reactions in immunocompromised patients which may preclude its use. Fourteen patients with a...

  • The Utility of Sputum Induction for Diagnosis of Pneumocystis Pneumonia in Immunocompromised Patients without Human Immunodeficiency Virus. LaRocque, Regina C.; Katz, Joel T.; Perruzzi, Priscilla; Baden, Lindsey R. // Clinical Infectious Diseases;11/15/2003, Vol. 37 Issue 10, p1380 

    Focuses on sputum induction (SI) vis-a-vis Pneumocystis pneumonia in immunocompromised patients without HIV in the U.S. Application of SI among immunocompromised patients; Importance of the application of SI for diagnosis of Pneumocystis pneumonia; Comparison of the clinical study on the outcome...

  • Pneumonia por Pneumocystis jiroveci (PPC) em pacientes com SIDA atendidos em hospitais da Baixada Fluminense, Rio de Janeiro, Brasil. Norberg, Antonio Neres; Melo Reis, Carlos Henrique; De Carvalho Queiroz, Margareth Maria; Ribeiro, Paulo César; Pile, Edwin; De Carvalho, Raimundo Wilson // Colombia Medica;abr-jun2009, Vol. 40 Issue 2, p213 

    Objetives: The authors investigated the P. jiroveci prevalence and the epidemiological pattern of individuals with HIV infection and pulmonary infection concomitantly. Method: Were collected 266 samples of bronchoalveolar lavae of the HIV infection patients from three hospitals from Baixada...

  • The Use of Polarization Microscopy in the Diagnosis of Pneumocystis Pneumonia. An, Teisa; Tabaczka, Pam // Archives of Pathology & Laboratory Medicine;Mar2004, Vol. 128 Issue 3, p363 

    Highlights the use of polarization microscopy in the diagnosis of pneumocystis pneumonia. Open lung biopsy on a human immunodeficiency virus-positive man with dyspnea and an interstitial infiltrate of both lungs; Detection of the polaroscopic refraction of Pneumocystic carinii after various...

  • Increase in Prevalence of Pneumocystis carinii Mutations in Patients with AIDS and P. carinii Pneumonia, in the United States and China. Kazanjian, Powel H.; Fisk, David; Armstrong, Wendy; Shulin, Qin; Liwei, Hua; Ke, Zhang; Meshnick, Steven // Journal of Infectious Diseases;5/1/2004, Vol. 189 Issue 9, p1684 

    This study of Pneumocystis carinii dihydropteroate synthase (DHPS) mutations in patients with AIDS who have P. carinii pneumonia compares the change in the prevalence of such mutations in the United States, where sulfa-drug prophylaxis is widespread, to that in China, where it is infrequent. The...

  • Retrospective review of Pneumocystis jirovecii pneumonia over two decades. Travis, J.; Hart, E.; Helm, J.; Duncan, T.; Vilar, J. // International Journal of STD & AIDS;Mar2009, Vol. 20 Issue 3, p200 

    The aim of the study was to compare a retrospective case note review of all cases of Pneumocystis carinii (now Pneumocystis jirovecii) pneumonia (PJP) over the period 1997-2004 at North Manchester General Hospital with a previous audit covering the years 1986-1995. During 1986-1995, 777 patients...

  • Pneumocystis jiroveci Genotypes in the Spanish Population. Montes-Cano, M. A.; de la Horra, C.; Martín-Juan, J.; Varela, J. M.; Torronteras, R.; Respaldiza, N.; Medrano, F. J.; Calderón, E. J. // Clinical Infectious Diseases;7/1/2004, Vol. 39 Issue 1, p123 

    This study describes the genotype distribution of Pneumocystis jiroveci in 79 respiratory samples obtained from 15 patients with acquired immunodeficiency syndrome (AIDS) with P. jiroveci pneumonia and 64 human immunodeficiency virus-negative subjects with different chronic pulmonary diseases....

  • Radioactively labelled diethylene triamine penta acetate lung scan in Pneum ocystis carinii pneumonia and asymptomatic HIV-positive patients. Dimian, Caroline O.; O'Doherty, Michael J.; Asboe, David; Page, Christopher J.; Entwisle, Kate; Bingham, James S. // International Journal of STD & AIDS;Aug1997, Vol. 8 Issue 8, p482 

    The objective of this study is to establish normal ranges for the assessment of lung permeability, using 99mTc DTPA (diethylene triamine penta acetate) aerosol by measuring the half-time of transfer from the lung in asymptomatic HIV-positive patients. Also to audit the use of the test in the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics